We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
+6.97%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.27B
AUM Growth
+$205M
Cap. Flow
-$194M
Cap. Flow %
-8.53%
Top 10 Hldgs %
63.25%
Holding
50
New
2
Increased
11
Reduced
7
Closed
13

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$66.5M
2
CI icon
Cigna
CI
+$64M
3
LDRH
LDR HOLDINGS CORP COM STK
LDRH
+$50.8M
4
COR icon
Cencora
COR
+$49.6M
5
NUVA
NuVasive, Inc.
NUVA
+$44.8M

Sector Composition

Rank Sector Weight
1 Healthcare 70.07%
2 Miscellaneous 29.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ARNA
26
DELISTED
Arena Pharmaceuticals Inc
ARNA
$18.4M 0.81%
1,050,000
ELOS
27
DELISTED
Syneron Medical Ltd
ELOS
$16.8M 0.74%
2,347,593
AMAG
28
DELISTED
AMAG Pharmaceuticals
AMAG
$15M 0.66%
611,390
+11,390
+2% +$285K
ELGX
29
DELISTED
Endologix Inc
ELGX
$12.8M 0.56%
100,000
-200,000
-67% -$25.6M
PLX icon
30
Protalix BioTherapeutics
PLX
$214M
$7.43M 0.33%
1,327,500
ATXS
31
DELISTED
Astria Therapeutics
ATXS
$6.16M 0.27%
16,667
DXTR
32
DELISTED
Dextera Surgical Inc.
DXTR
$1.58M 0.07%
837,483
BIIB icon
33
Biogen
BIIB
$31.9B
-275,000
Closed -$66.5M
CI icon
34
Cigna
CI
$76.3B
-500,000
Closed -$64M
COR icon
35
Cencora
COR
$61.7B
-625,000
Closed -$49.6M
DRRX
36
DELISTED
DURECT Corp
DRRX
-600,000
Closed -$7.32M
OSUR icon
37
OraSure Technologies
OSUR
$239M
-707,559
Closed -$4.18M
BIOL
38
DELISTED
Biolase, Inc.
BIOL
-427
Closed -$6.24M
NUVA
39
DELISTED
NuVasive, Inc.
NUVA
-750,000
Closed -$44.8M
GNMK
40
DELISTED
GenMark Diagnostics, Inc
GNMK
-649,097
Closed -$5.65M
WMGI
41
DELISTED
Wright Medical Group Inc
WMGI
-2,475,000
Closed -$43M
ARIA
42
DELISTED
Ariad Pharmaceuticals Inc
ARIA
-4,000,000
Closed -$29.6M
SQNM
43
DELISTED
SEQUENOM INC NEW
SQNM
-17,325,000
Closed -$15.8M
LDRH
44
DELISTED
LDR HOLDINGS CORP COM STK
LDRH
-1,375,000
Closed -$50.8M
EPRS
45
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
-1,847,500
Closed -$835K

Similar funds

Camber Capital Management's Q3 2016 Portfolio in Review

As of Q3 2016, Camber Capital Management held 50 positions worth $2.27B, up 9.9% from $2.07B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Camber Capital Management withdrew a net $194M in Q3 2016, closing 13 positions and reducing 7 holdings. Its most notable exit was Biogen, an estimated $66.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 79% a quarter earlier, followed by Miscellaneous.

Against the trend, Camber Capital Management opened a new position in CONMED worth $30M.

  • Camber Capital Management's largest Q3 2016 buy was CONMED: 750,000 shares worth $30M.
  • Camber Capital Management added most to Perrigo in Q3 2016, an estimated $59.3M increase.
  • Camber Capital Management's biggest Q3 2016 reduction was Endologix Inc, cutting an estimated $25.6M.
  • Camber Capital Management fully exited Biogen in Q3 2016, selling an estimated $66.5M.
  • Camber Capital Management's ten largest holdings make up 63% of its $2.27B portfolio in Q3 2016.
  • Camber Capital Management opened 2 new positions and closed 13 in Q3 2016.
  • Camber Capital Management's portfolio value rose 9.9% quarter-over-quarter to $2.27B.

Based on Camber Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.